NASDAQ:GLPGGALAPAGOS NV/S Stock Price, Forecast & News

GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GLPG stock has increased by 2.5% and is now trading at $190.75.
View which stocks have been most impacted by Coronavirus.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for GALAPAGOS NV/S.

GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for GALAPAGOS NV/S.

14 equities research analysts have issued 1-year price targets for GALAPAGOS NV/S's stock. Their forecasts range from $155.00 to $290.00. On average, they expect GALAPAGOS NV/S's stock price to reach $219.58 in the next year. This suggests a possible upside of 15.1% from the stock's current price.
View analysts' price targets for GALAPAGOS NV/S.

Press coverage about GLPG stock has trended very negative this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. GALAPAGOS NV/S earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about GALAPAGOS NV/S.

Some companies that are related to GALAPAGOS NV/S include ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), UCB (UCBJF), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Shiseido (SSDOY), Beigene (BGNE), Merck KGaA (MKGAF), Alnylam Pharmaceuticals (ALNY), Horizon Therapeutics (HZNP), Catalent (CTLT) and Teva Pharmaceutical Industries (TEVA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), argenx (ARGX), NVIDIA (NVDA), AbbVie (ABBV), Pharming Group (PHGUF), Trade Desk (TTD), Biogen (BIIB) and Collegium Pharmaceutical (COLL).

(GLPG) raised $161 million in an initial public offering (IPO) on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers.

GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG."

GALAPAGOS NV/S's stock is owned by a variety of institutional and retail investors. Top institutional investors include Public Employees Retirement Association of Colorado (0.08%), Envestnet Asset Management Inc. (0.07%), Peregrine Capital Management LLC (0.05%), Dorsey Wright & Associates (0.05%), Henry James International Management Inc. (0.04%) and Russell Investments Group Ltd. (0.02%).

GLPG stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Dorsey Wright & Associates, Trexquant Investment LP, RMB Capital Management LLC, and Russell Investments Group Ltd..

GLPG stock was bought by a variety of institutional investors in the last quarter, including Public Employees Retirement Association of Colorado, Virtu Financial LLC, Envestnet Asset Management Inc., Henry James International Management Inc., Venturi Wealth Management LLC, FDx Advisors Inc., UBS Group AG, and Altium Wealth Management LLC.

Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GLPG stock can currently be purchased for approximately $190.75.

GALAPAGOS NV/S has a market capitalization of $12.45 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe.

The official website for GALAPAGOS NV/S is www.glpg.com.

GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected]